Molecular Profile in Endometrial Carcinoma: Can We Predict the Lymph Node Status? A Systematic Review and Meta-analysis

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Apr 5

PMID 38578538

Authors

Ana Luzarraga Aznar

Vicente Bebia

Natalia Rodriguez Gomez-Hidalgo

Carlos Lopez-Gil

Marta Miguez

Eva Colas

Asuncion Perez-Benavente

Antonio Gil-Moreno

Silvia Cabrera

Affiliations

Soon will be listed here.

Abstract

Purpose: Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.

Methods: A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.

Results: Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).

Conclusions: The presence of LNM seems to be influenced by molecular classification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.

Citing Articles

Clinicopathological characteristics of endometrial carcinoma with different molecular subtypes and their correlation with lymph node metastasis.

Meng Y, Feng J, Yang J, Yin H Am J Cancer Res. 2024; 14(8):3994-4003.

PMID: 39267670 PMC: 11387856. DOI: 10.62347/FPUJ8382.

References

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza M, Marnitz S . ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1):12-39. DOI: 10.1136/ijgc-2020-002230. View

Mitchard J, Hirschowitz L . Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology. 2003; 42(4):372-8. DOI: 10.1046/j.1365-2559.2003.01603.x. View

Han G, Sidhu D, Duggan M, Arseneau J, Cesari M, Clement P . Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013; 26(12):1594-604. DOI: 10.1038/modpathol.2013.102. View

Gilks C, Oliva E, Soslow R . Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013; 37(6):874-81. DOI: 10.1097/PAS.0b013e31827f576a. View

Abu-Rustum N, Khoury-Collado F, Pandit-Taskar N, Soslow R, Dao F, Sonoda Y . Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?. Gynecol Oncol. 2009; 113(2):163-9. PMC: 3959736. DOI: 10.1016/j.ygyno.2009.01.003. View

Mariani A, Dowdy S, Cliby W, Gostout B, Jones M, Wilson T . Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008; 109(1):11-8. PMC: 3667391. DOI: 10.1016/j.ygyno.2008.01.023. View

Stelloo E, Nout R, Naves L, Ter Haar N, Creutzberg C, Smit V . High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol Oncol. 2014; 133(2):197-204. DOI: 10.1016/j.ygyno.2014.02.012. View

Plotkin A, Kuzeljevic B, de Villa V, Thompson E, Gilks C, Clarke B . Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. Int J Gynecol Pathol. 2020; 39(6):537-545. DOI: 10.1097/PGP.0000000000000654. View

10.

Kommoss S, McConechy M, Leung S, Bunz A, Magrill J, Britton H . Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018; 29(5):1180-1188. DOI: 10.1093/annonc/mdy058. View

11.

Talhouk A, McConechy M, Leung S, Li-Chang H, Kwon J, Melnyk N . A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2):299-310. PMC: 4506381. DOI: 10.1038/bjc.2015.190. View

12.

Talhouk A, McConechy M, Leung S, Yang W, Lum A, Senz J . Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5):802-813. DOI: 10.1002/cncr.30496. View

13.

Stelloo E, Nout R, Osse E, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016; 22(16):4215-24. DOI: 10.1158/1078-0432.CCR-15-2878. View

14.

Leon-Castillo A, de Boer S, Powell M, Mileshkin L, MacKay H, Leary A . Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020; 38(29):3388-3397. PMC: 7527156. DOI: 10.1200/JCO.20.00549. View

15.

Jamieson A, Thompson E, Huvila J, Leung S, Lum A, Morin C . Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. Gynecol Oncol. 2022; 165(2):376-384. DOI: 10.1016/j.ygyno.2022.01.025. View

16.

Leon-Castillo A, Horeweg N, Peters E, Rutten T, Ter Haar N, Smit V . Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol Oncol. 2022; 164(3):577-586. DOI: 10.1016/j.ygyno.2022.01.007. View

17.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

18.

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J . ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015; 27(1):16-41. DOI: 10.1093/annonc/mdv484. View

19.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

20.

Bayramoglu D, Secilmis Kerimoglu O, Bayramoglu Z, Cintesun E, Sahin G, Karabagli P . Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods. Ginekol Pol. 2022; 94(1):3-11. DOI: 10.5603/GP.a2021.0177. View